Price T Rowe Associates Inc Arcus Biosciences, Inc. Transaction History

Price T Rowe Associates Inc

$836 Billion
Q2 2024

A detailed history of Price T Rowe Associates Inc transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 36,498 shares of RCUS stock, worth $558,054. This represents 0.0% of its overall portfolio holdings.

Number of Shares

36,498

Previous 34,764 4.99%

Holding current value

$558,054

Previous $657,000 15.37%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$14.59 - $18.48 $25,299 - $32,044	1,734 Added 4.99%	36,498 $556,000
Q1 2024 May 15, 2024	BUY	$14.83 - $20.18 $28,265 - $38,463	1,906 Added 5.8%	34,764 $657,000
Q4 2023 Feb 14, 2024	BUY	$13.43 - $19.63 $22,092 - $32,291	1,645 Added 5.27%	32,858 $628,000
Q3 2023 Nov 14, 2023	SELL	$17.62 - $23.54 $4.41 Million - $5.89 Million	-250,407 Reduced 88.92%	31,213 $561,000
Q2 2023 Aug 14, 2023	BUY	$16.97 - $22.03 $35,467 - $46,042	2,090 Added 0.75%	281,620 $5.72 Million
Q1 2023 May 15, 2023	SELL	$15.96 - $23.15 $3.61 Million - $5.24 Million	-226,217 Reduced 44.73%	279,530 $5.1 Million
Q4 2022 Feb 14, 2023	BUY	$19.7 - $35.71 $9.49 Million - $17.2 Million	481,848 Added 2016.18%	505,747 $10.5 Million
Q3 2022 Nov 14, 2022	BUY	$23.23 - $30.07 $143,979 - $186,373	6,198 Added 35.01%	23,899 $626,000
Q2 2022 Aug 15, 2022	SELL	$17.23 - $37.73 $29,911 - $65,499	-1,736 Reduced 8.93%	17,701 $449,000
Q1 2022 May 16, 2022	BUY	$28.92 - $41.83 $46,908 - $67,848	1,622 Added 9.1%	19,437 $613,000
Q4 2021 Feb 14, 2022	SELL	$31.38 - $48.47 $24,131 - $37,273	-769 Reduced 4.14%	17,815 $721,000
Q3 2021 Nov 15, 2021	SELL	$26.93 - $37.68 $1,050 - $1,469	-39 Reduced 0.21%	18,584 $648,000
Q2 2021 Aug 16, 2021	SELL	$22.75 - $35.77 $59,423 - $93,431	-2,612 Reduced 12.3%	18,623 $511,000
Q1 2021 May 17, 2021	SELL	$26.16 - $41.39 $235 - $372	-9 Reduced 0.04%	21,235 $596,000
Q4 2020 Feb 16, 2021	BUY	$17.0 - $32.36 $361,148 - $687,455	21,244 New	21,244 $551,000

Others Institutions Holding RCUS

# of Institutions

207

Shares Held

49M

Call Options Held

173K

Put Options Held

151K

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.1B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Arcus Biosciences, Inc. Transaction History